**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 79618

**Manuscript Type:** EDITORIAL

**Metabolic-associated fatty liver disease: New nomenclature and approach with hot debate**

Fouad Y *et al*. Metabolic-associated fatty liver disease

Yasser Fouad

**Yasser Fouad,** Department of Gastroenterology and Endemic Medicine, Minia University, Minia 19111, Egypt

**Author contributions:** Fouad Y wrote and revised the editorial.

**Corresponding author: Yasser Fouad, MD, Professor,** Department of Gastroenterology and Endemic Medicine, Minia University, El Omoumy Rd., ARD SHALABY, EL MENIA, Minia 19111, Egypt. yasserfouad10@yahoo.com

**Received:** August 29, 2022

**Revised:** November 19, 2022

**Accepted:** January 31, 2023

**Published online:**

**Abstract**

An international panel recently proposed an update to the terminology and diagnostic criteria for fatty liver disease. The experts proposed a change in the nomenclature from non-alcoholic fatty liver disease (NAFLD) to metabolic (dysfunction)-associated fatty liver disease (MAFLD). This single-letter change, we believe, heralds the dawn of a new era in clinical practice and in clinical and basic research as well. The new nomenclature with the easily applicable approach has stimulated the enthusiasm of the researchers worldwide, resulting in a large number of publications over the past two years. Several recent studies have provided tremendous evidence of the superiority of the MAFLD criteria over the NAFLD criteria. Many studies in different geographic areas of the world including the United States, Europe, and Asia on a large number of patients proved that the utility of MAFLD criteria was higher than that of the NAFLD criteria in different aspects of fatty liver diseases. Consequently, many societies, physician and nurse groups, health stakeholders, representatives of regulatory sciences, and others endorsed the new nomenclature. Here we highlight the endorsement of the new name by different societies and groups and the outcome of different studies on the new nomenclature in addition to a short discussion of the debate by some experts.

**Key Words:** Non-alcoholic fatty liver disease; Metabolic-associated fatty liver disease; Liver disease; Fibrosis; New nomenclature; Redefinition

Fouad Y. Metabolic-associated fatty liver disease: New nomenclature and approach with hot debate. *World J Hepatol* 2023; In press

**Core Tip:** An international panel recently proposed an update to the terminology and diagnostic criteria for fatty liver disease. The authors proposed a change in the nomenclature from non-alcoholic fatty liver disease (NAFLD) to metabolic (dysfunction)-associated fatty liver disease (MAFLD). Several studies have been published recently, and showed tremendous evidence of the superiority of MAFLD criteria over NAFLD criteria. Consequently, many societies, physician and nurse groups, health stakeholders, representatives of regulatory sciences, and others endorsed the new nomenclature.

**INTRODUCTION**

The World Health Organization (WHO) has motivated scientists, doctors, and healthcare providers to use the appropriate medical terms and change the terms according to the patient's interest and the medical care provided. This call by the WHO was to overcome the stigmas and inaccuracies that may confer upon people, regions, and economies[1]

In the recent medical history, renaming of the diseases involved primary biliary cirrhosis, schizophrenia, epilepsy, autism, and others with ongoing trials to change the term ‘’noncommunicable diseases’’ to a better positive name to gain more medical support by governments, societies, and stakeholders[2]

Since 1980 when the non-alcoholic fatty liver disease (NAFLD) was introduced[3], several trials have been carried out to rename the disease by different scientists and societies for different reasons. In 2019, Eslam *et al*[4] proposed changing the traditional NAFLD to metabolic dysfunction-associated liver disease (MAFLD). The single-letter change means a lot for researchers, physicians, and patients. The authors explained their vision of new nomenclature by linking the fatty liver to the metabolic syndrome which is the most common and most serious etiology of fatty liver diseases and under-evaluated when using the older nomenclature. Moreover, the new nomenclature gives the clinical community a chance to avoid the stigma of alcohol intake, avoid the negativity of NAFLD nomenclature, and overcomes trivialization[2]. The simplified criteria for diagnosis of MAFLD were put forward by consensus of an international panel of hepatologists in 2020[5]. These criteria pave the way for easy diagnosis of fatty liver diseases because of easy applicability. The consensus considered the diagnosis of MAFLD based on the presence of steatosis by imaging or histopathology in addition to the presence of diabetes mellitus or obesity/overweight or two out of seven metabolic dysfunction criteria (Figure 1). The new nomenclature and approach better clarify the role of metabolic dysfunctions in fatty liver disease and make the fatty liver closer to its pathophysiology.

The new nomenclature with the easily applicable approach stimulated the enthusiasm of researchers worldwide, resulting in a large number of publications over the last two years. Several studies have been published recently, showing tremendous evidence of the superiority of MAFLD criteria over NAFLD criteria. Many studies in different geographic areas of the world including the United States (US), Europe, and Asia on a large number of patients proved that the utility of MAFLD criteria was higher than that of the NAFLD criteria in different aspects of fatty liver diseases.

Among the many important findings, MAFLD criteria could better identify patients at risk of liver fibrosis than the NAFLD criteria in the American population[6]. High diagnostic ability of fatty liver index in the detection of steatosis was seen in patients with MAFLD[7]. Fibrosis-4 index and NAFLD fibrosis score could confidently be used to exclude advanced fibrosis in overweight, obese, and severely obese patients with MAFLD[8]. MAFLD is associated with a higher incidence of hepatocellular carcinoma[9]. MAFLD (not NAFLD) predicts extrahepatic malignancy[10]. MAFLD was better than NAFLD in identifying patients at high risk of renal diseases[11]. In a recent meta-analysis, MAFLD was associated with increased severity of COVID-19[12]. Renaming to MAFLD increases awareness of the disease among primary care providers and physicians in other specialties[13]. Change to MAFLD has a positive impact on clinical trials[14,15] MAFLD identifies the severity of the coexistence of fatty liver disease with other liver diseases[16,17]

Being convinced by the reasons for changing nomenclature, evidence of the superiority of the new name MAFLD, and the benefits of the new nomenclature, many international societies, patient groups, stakeholders, nurse groups, and representatives of pharmacist and regulatory sciences have endorsed the new nomenclature (Table 1). In an unprecedented manner, a unique gathering of more than a thousand international experts from more than 135 countries worldwide signed an agreement on a global multi-stakeholder endorsement of the MAFLD definition published recently.

Two major hepatology societies, The European Association for Study of the Liver and The American Association for the Study of Liver Diseases, have not endorsed the new name yet till writing this editorial. The debate from these societies focused mainly on the prematurity of change[18]. One of the main debates is about non-metabolic or lean NAFLD. Evidence proved that the non-metabolic NAFLD group seems to be comparable to subjects with no fatty liver in terms of cardiovascular-related mortality as well as all-cause mortality. Moreover, the non-metabolic NAFLD group seems to be at a very low risk of fibrosis (0.8%)[19]. Another concern was about pediatric NAFLD. In a recent study involving 1446 US adolescents aged 12–18 years from the National Health and Nutrition Examination Survey III, MAFLD criteria were met by most of these US adolescents with elastographic evidence of steatosis[20]. Additional debate was about clinical trials. In a recently published paper, a group of researchers declared that the new name and approach with positive inclusion criteria lead to easier recruitment of patients and are more likely to give positive results[21].  Being in the era of evidence-based medicine, we believe that the need for an evidence-based debate is mandatory. Once again, the MAFLD conceptual framework removes the concept that there is no alcohol involvement, links the liver disease which is commonly seen in metabolic dysregulation with its systemic effects, and performs better in patient identification, risk stratification, disease awareness, and networking with metabolic disease physicians[22,23].

The important question in the current situation is why some experts do not change their attitude toward the new nomenclature despite the obvious conspicuous evidence. The answer is not clear although, pleasingly, since the very beginning, the weight of evidence appears to have led to the persuasion of an ever-increasing number of stakeholders on the increasing benefits. Another important issue is that experts who advocate against the redefinition despite the robust evidence should explain to the hepatology community how and why we discard the rapidly progressive growing body of new literature[24].

**CONCLUSION**

In summary, we have a redefinition of a very prevalent disease worldwide. The new nomenclature MAFLD is simple, with superior utility, and is supported by a tremendous amount of evidence. It is endorsed by many societies and full global adoption is a matter of time.

**REFERENCES**

1 **Gladstonemay R.** WHO urges more care in naming diseases.New York, NY: New York Times. [Internet] [accessed 8 May 2015]. Available from: https://www.seattletimes.com/nation-world/who-urges-more-care-in-naming-diseases/

2 **Fouad Y**, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Renaming 'NAFLD' to 'MAFLD'. *Liver Int* 2020; **40**: 1254-1261 [PMID: 32301554 DOI: 10.1111/liv.14478]

3 **Ludwig J**, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980; **55**: 434-438 [PMID: 7382552]

4 **Eslam M**, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology* 2020; **158**: 1999-2014.e1 [PMID: 32044314 DOI: 10.1053/j.gastro.2019.11.312]

5 **Eslam M**, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol* 2020; **73**: 202-209 [PMID: 32278004 DOI: 10.1016/j.jhep.2020.03.039]

6 **Wang X**, Wu S, Yuan X, Chen S, Fu Q, Sun Y, Lan Y, Hu S, Wang Y, Lu Y, Qu S, Wang L. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study. *J Clin Endocrinol Metab* 2022; **107**: e745-e755 [PMID: 34467980 DOI: 10.1210/clinem/dgab644]

7 **Kim D**, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. *J Hepatol* 2021; **75**: 1284-1291 [PMID: 34380057 DOI: 10.1016/j.jhep.2021.07.035]

8 **Eren F**, Kaya E, Yilmaz Y. Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals. *Eur J Gastroenterol Hepatol* 2022; **34**: 98-103 [PMID: 32976186 DOI: 10.1097/MEG.0000000000001946]

9 **Lin YP**, Wang PM, Chuang CH, Yong CC, Liu YW, Huang PY, Yao CC, Tsai MC. Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study. *Front Oncol* 2022; **12**: 816472 [PMID: 35186751 DOI: 10.3389/fonc.2022.816472]

10 **Lin S**, Huang J, Wang M, Kumar R, Liu Y, Liu S, Wu Y, Wang X, Zhu Y. Comparison of MAFLD and NAFLD diagnostic criteria in real world. *Liver Int* 2020; **40**: 2082-2089 [PMID: 32478487 DOI: 10.1111/liv.14548]

11 **Liang Y**, Chen H, Liu Y, Hou X, Wei L, Bao Y, Yang C, Zong G, Wu J, Jia W. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China. *J Clin Endocrinol Metab* 2022; **107**: 88-97 [PMID: 34508601 DOI: 10.1210/clinem/dgab641]

12 **Pan L**, Huang P, Xie X, Xu J, Guo D, Jiang Y. Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis. *Dig Liver Dis* 2021; **53**: 153-157 [PMID: 33011088 DOI: 10.1016/j.dld.2020.09.007]

13 **Fouad Y**, Gomaa A, Semida N, Ghany WA, Attia D. Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. *J Hepatol* 2021; **74**: 1254-1256 [PMID: 33582129 DOI: 10.1016/j.jhep.2020.12.035]

14 **Pan Z**, Fan JG, Eslam M. An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. *Curr Opin Pharmacol* 2021; **60**: 170-176 [PMID: 34455284 DOI: 10.1016/j.coph.2021.07.007]

15 **Eslam M**, George J. MAFLD: Now is the time to capitalize on the momentum. *J Hepatol* 2021; **74**: 1262-1263 [PMID: 33587953 DOI: 10.1016/j.jhep.2021.02.002]

16 **Mak LY**, Yuen MF, Seto WK. Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". *J Hepatol* 2020; **73**: 1573-1574 [PMID: 32951910 DOI: 10.1016/j.jhep.2020.07.008]

17 **van Kleef LA**, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, Janssen HLA, de Knegt RJ, Sonneveld MJ. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. *JHEP Rep* 2021; **3**: 100350 [PMID: 34557660 DOI: 10.1016/j.jhepr.2021.100350]

18 **Younossi ZM**, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, Cohen DE, Loomba R. From NAFLD to MAFLD: Implications of a Premature Change in Terminology. *Hepatology* 2021; **73**: 1194-1198 [PMID: 32544255 DOI: 10.1002/hep.31420]

19 **Tsutsumi T**, Kawaguchi T, Nakano D, Torimura T. Atherosclerotic cardiovascular disease in non-metabolic nonalcoholic fatty liver disease. *Hepatol Res* 2022; **52**: 317-319 [PMID: 35229393 DOI: 10.1111/hepr.13738]

20 **Ciardullo S**, Carbone M, Invernizzi P, Perseghin G. Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents. *Hepatol Commun* 2022; **6**: 2070-2078 [PMID: 35470984 DOI: 10.1002/hep4.1969]

21 **Eslam M**, Ahmed A, Després JP, Jha V, Halford JCG, Wei Chieh JT, Harris DCH, Nangaku M, Colagiuri S, Targher G, Joshi S, Byrne CD, Khunti K, Nguyen MH, Gish RG, George J. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. *Lancet Gastroenterol Hepatol* 2021; **6**: 743-753 [PMID: 34265276 DOI: 10.1016/S2468-1253(21)00132-1]

22 **Méndez-Sánchez N**, Díaz-Orozco L, Córdova-Gallardo J. Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience. *J Hepatol* 2021; **75**: 221-222 [PMID: 33892008 DOI: 10.1016/j.jhep.2021.04.021]

23 **Eslam M**, Ratziu V, George J. Yet more evidence that MAFLD is more than a name change. *J Hepatol* 2021; **74**: 977-979 [PMID: 33453331 DOI: 10.1016/j.jhep.2020.12.025]

24 **Fouad Y**, Dufour JF, Zheng MH, Bollipo S, Desalegn H, Grønbaek H, Gish RG. The NAFLD-MAFLD debate: Is there a Consensus-on-Consensus methodology? *Liver Int* 2022; **42**: 742-748 [PMID: 35182007 DOI: 10.1111/liv.15197]

25 **Eslam M**, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. *Hepatol Int* 2020; **14**: 889-919 [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2]

26 **Fouad Y**, Esmat G, Elwakil R, Zakaria S, Yosry A, Waked I, El-Razky M, Doss W, El-Serafy M, Mostafa E, Anees M, Sakr MA, AbdelAty N, Omar A, Zaki S, Al-Zahaby A, Mahfouz H, Abdalla M, Albendary M, Hamed AK, Gomaa A, Hasan A, Abdel-Baky S, El Sahhar M, Shiha G, Attia D, Saeed E, Kamal E, Bazeed S, Mehrez M, Abdelaleem S, Gaber Y, Abdallah M, Salama A, Tawab DA, Nafady S. The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. *Saudi J Gastroenterol* 2022; **28**: 3-20 [PMID: 35083973 DOI: 10.4103/sjg.sjg\_357\_21]

27 **Shiha G**, Alswat K, Al Khatry M, Sharara AI, Örmeci N, Waked I, Benazzouz M, Al-Ali F, Hamed AE, Hamoudi W, Attia D, Derbala M, Sharaf-Eldin M, Al-Busafi SA, Zaky S, Bamakhrama K, Ibrahim N, Ajlouni Y, Sabbah M, Salama M, Anushiravani A, Afredj N, Barakat S, Hashim A, Fouad Y, Soliman R. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. *Lancet Gastroenterol Hepatol* 2021; **6**: 57-64 [PMID: 33181119 DOI: 10.1016/S2468-1253(20)30213-2]

28 **Clayton M**, Fabrellas N, Luo J, Alghamdi MG, Hafez A, Qadiri TA, Owise N, Attia D. From NAFLD to MAFLD: Nurse and allied health perspective. *Liver Int* 2021; **41**: 683-691 [PMID: 33453067 DOI: 10.1111/liv.14788]

29 **Mendez-Sanchez N**, Arrese M, Gadano A, Oliveira CP, Fassio E, Arab JP, Chávez-Tapia NC, Dirchwolf M, Torre A, Ridruejo E, Pinchemel-Cotrim H, Castellanos Fernández MI, Uribe M, Girala M, Diaz-Ferrer J, Restrepo JC, Padilla-Machaca M, Dagher L, Gatica M, Olaechea B, Pessôa MG, Silva M. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. *Lancet Gastroenterol Hepatol* 2021; **6**: 65-72 [PMID: 33181118 DOI: 10.1016/S2468-1253(20)30340-X]

30 **Nan Y**, An J, Bao J, Chen H, Chen Y, Ding H, Dou X, Duan Z, Fan J, Gao Y, Han T, Han Y, Hu P, Huang Y, Huang Y, Jia J, Jiang J, Jiang Y, Li J, Li J, Li R, Li S, Li W, Li Y, Lin S, Liu J, Liu S, Lu L, Lu Q, Luo X, Ma X, Rao H, Ren H, Ren W, Shang J, Shi L, Su M, Wang B, Wang R, Wei L, Wen Z, Wu B, Wu J, Xin S, Xing H, Xu J, Yan M, Yang J, Yang J, Yang L, Yang Y, Yu Y, Zhang L, Zhang L, Zhang X, Zhang Y, Zhang Y, Zhao J, Zhao S, Zheng H, Zhou Y, Zhou Y, Zhuang H, Zuo W, Xu X, Qiao L. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. *J Hepatol* 2021; **75**: 454-461 [PMID: 34019941 DOI: 10.1016/j.jhep.2021.05.003]

31 **El-Shabrawi M**, Memon I, Attia D, El-Koofy NM. The International Society of Tropical Paediatrics (ISTP) endorses the redefinition of fatty liver disease. *J Hepatol* 2022; **76**: 738-739 [PMID: 34813920 DOI: 10.1016/j.jhep.2021.11.016]

32 **Shaltout I**, Alkandari H, Fouad Y, Hamed AE. Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease. *J Hepatol* 2022; **76**: 739-740 [PMID: 34875311 DOI: 10.1016/j.jhep.2021.11.027]

33 **Chan WK**, Tan SS, Chan SP, Lee YY, Tee HP, Mahadeva S, Goh KL, Ramli AS, Mustapha F, Kosai NR, Raja Ali RA. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. *J Gastroenterol Hepatol* 2022; **37**: 795-811 [PMID: 35080048 DOI: 10.1111/jgh.15787]

34 **Fouad Y**, Palmer M, Chen M, Regev A, Banerjee R, Myers R, Riccio R, Torstenson R, Younes R, Arora PS, Landgren H, Karsdal MA, Blake M, Shapiro DA, Gruss HJ, Sheikh MY, Attia D, Bollipo S, Smith AD, Freilich B, Gish RG, Schuppan D. Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science. *J Clin Transl Hepatol* 2022; **10**: 374-382 [PMID: 35528969 DOI: 10.14218/JCTH.2021.00408]

35 **Shiha G**, Korenjak M, Eskridge W, Casanovas T, Velez-Moller P, Högström S, Richardson B, Munoz C, Sigurðardóttir S, Coulibaly A, Milan M, Bautista F, Leung NWY, Mooney V, Obekpa S, Bech E, Polavarapu N, Hamed AE, Radiani T, Purwanto E, Bright B, Ali M, Dovia CK, McColaugh L, Koulla Y, Dufour JF, Soliman R, Eslam M. Redefining fatty liver disease: an international patient perspective. *Lancet Gastroenterol Hepatol* 2021; **6**: 73-79 [PMID: 33031758 DOI: 10.1016/S2468-1253(20)30294-6]

36 **Méndez-Sánchez N**, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global multi-stakeholder endorsement of the MAFLD definition. *Lancet Gastroenterol Hepatol* 2022; **7**: 388-390 [PMID: 35248211 DOI: 10.1016/S2468-1253(22)00062-0]

37 **Romero-Gómez M**, Ampuero J. Looking for a new name for non-alcoholic fatty liver disease in Spanish: esteatosis hepática metabólica (EHmet). *Rev Esp Enferm Dig* 2021; **113**: 161-163 [PMID: 33573385 DOI: 10.17235/reed.2021.7862/2021]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** EASL, 14229; APASL, 2217.

**Peer-review started:** August 29, 2022

**First decision:** November 17, 2022

**Article in press:** November 19, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Egypt

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Ko HL, Singapore; Kocak A, Turkey; Li HL, China **S-Editor:** Liu GL **L-Editor:** Wang TQ **P-Editor:** Liu GL

**Figure Legends**

****

**Figure 1 Criteria for diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease.** NAFLD: Non-alcoholic fatty liver disease; MAFLD: Metabolic-associated fatty liver disease; HBV: Hepatitis B virus; HCV: Hepatitis B virus; HDL: High-density lipoprotein; HbA1c: Hemoglobin A1c; HOMA: Homeostasis model assessment.

**Table 1 Metabolic-associated fatty liver disease endorsement by societies, groups, and stakeholders**

|  |  |  |
| --- | --- | --- |
| **Type of endorsement** | **Endorsed by** | **Ref.** |
| Guidelines | APASL | [25] |
| Guidelines | Egyptian EMRG group | [26] |
| Consensus statement | Middle East and North Africa group | [27] |
| View point (perspectives) | International nurse and allied health groups | [28] |
| Position statement | ALEH | [29] |
| Position statement | The Chinese Society of Hepatology | [30] |
| Position statement | ISTP | [31] |
| Position statement | Arabic Association for the Study of Diabetes and Metabolism | [32] |
| Consensus statement | Malaysian Society of Gastroenterology and Hepatology | [33] |
| Viewpoint (perspectives) | International leaders in regulatory science and drug development | [34] |
| Position statement | International representatives of patient advocacy groups | [35] |
| Letter of endorsement | Global multi-stakeholder from more than 135 countries worldwide | [36] |
| Editorial of endorsement | Spanish Society of Gastroenterology | [37] |

APASL: Asian Pacific Association for the Study of the Liver; EMRG: Egyptian MAFLD Research Group; ISTIP: The International Society of Tropical Pediatrics; ALEH: The Latin American Association for the Study of the Liver.